Kodak Stock Surges Over 1,300% After Securing Government Drug Manufacturing Loan
Eastman Kodak sees its stock skyrocket after receiving a $765 million federal loan to produce generic drug ingredients under the Defense Production Act. The historic photography company plans to leverage its chemical manufacturing expertise to address critical national shortages.
Eastman Kodak shares experience historic gains, soaring over 1,300% this week after the U.S. government awards the company a $765 million loan. President Trump announces this as the 33rd use of the Defense Production Act to mobilize Kodak in producing generic active pharmaceutical ingredients. The massive surge pushes the company's market capitalization from just $115 million to over $1.5 billion in a matter of days.
The iconic photography pioneer establishes a new division called Kodak Pharmaceuticals to address chronic national shortages of essential medical components identified by the FDA. Kodak plans to expand its existing facilities in Rochester, New York and St. Paul, Minnesota to handle this new production. Executive Chairman Jim Continenza states that the company relies on its vast infrastructure and deep expertise in chemicals manufacturing to build a reliable American pharmaceutical supply chain.
This dramatic pivot offers a potential lifeline to the 131-year-old company, which previously filed for bankruptcy in 2012 as digital cameras disrupted its core film business. The move into pharmaceuticals actually marks a return to an older venture, as Kodak previously manufactured nonprescription medicines like aspirin in the 1990s before selling off that business. By shifting its chemical production capabilities toward critical healthcare needs, Kodak attempts to reinvent itself once again in the face of a global pandemic.